Phibro Animal Health Raises Guidance at BofA Conference as Zoetis MFA Integration Advances

She also cited continued growth in other segments, including 13% growth in vaccines and 9% growth in nutritional specialties for the quarter. Bendheim said the strong first half gave the company confidence to raise guidance for revenue, EBITDA, and adjusted net income, and she described investor feedback as “very positive.”Within MFAs, Bendheim noted the legacy MFA business declined 5% in the quarter due to the timing of an order from a large customer for an API product. She said that, normalized for the ti ...